From November last year, the NuvaRing is listed on the Pharmaceutical Benefits Scheme (PBS), allowing Australians subsidised access to another form of contraception.
The NuvaRing is a contraceptive device that is inserted into the vagina and releases a combination of oestrogen and progesterone to inhibit ovulation and increase cervical mucous preventing sperm’s ability to penetrate the uterus. It is worn for three weeks at a time, before being removed for a week for a monthly bleed and then replaced with a new ring. The NuvaRing is a suitable contraceptive for people who may struggle with taking a daily pill.
Health Minister Mark Butler announced the change in November, which will see the cost of NuvaRing slashed by around two-thirds.
Previously, the contraceptive cost individuals more than $270 a year. However, in November, a three-month script for NuvaRing was reduced to $31.60, saving patients at least $107.60 annually. In January of this year, this cost was reduced again further with a three-month script now costing no more than $25.
This change is one of many in an overhaul implemented by the Federal Government to reduce barriers to contraception in Australia.
Currently Australia has one of the lowest uptakes of long-acting reversible contraceptives (LARC) due in part to a lack of affordability and access.
“These changes to MBS and expanded options though the PBS will remove cost and access barriers so that more women can choose the contraceptive option that works best for them,” said Minister Butler.
According to the Federal Government, changes linked to LARC will benefit around 300,000 women each year, saving each person $400 in out-of-pocket costs.
For information on contraceptives and decision-making tools and courses, click here.
